Epidemiology and Control of Mansonella Perstans Infection in Uganda

• Sponsor: DBL -Institute for Health Research and Development (Other)
• Overall Status: Completed
• CT.gov ID: NCT00215280
• Collaborator: Ministry of Health, Uganda (Other)
• Enrollment: 1,000
• Location: 1
• Duration (Months): 3
• Patients Per Site Per Month: 330.8

Study Details

Study Description

Brief Summary

Mansonella perstans (M. perstans) infection is widespread in Uganda. Knowledge about the epidemiology of this infection, and of the morbidity it induces is poor, and no effective treatment is available. The study aims at providing data on diagnostic, epidemiological, morbidity and treatment aspects of M. perstans infections in Uganda.

Condition or Disease	Intervention/Treatment	Phase
Mansonelliasis; Pruritus; Lymphoedema; Abdominal Pains	Drug: ivermectin and albendazole	N/A

Detailed Description

Overall objective: to investigate diagnostic, epidemiological and treatment aspects of M. perstans in Uganda with relevance to control

Specific objectives:

1. To establish the pattern of diurnal periodicity of M. perstans microfilaraemia in humans

2. To establish the patterns of M. perstans microfilaraemia and possible clinical manifestations related to this infection in two communities with medium to high endemicity

3. To determine the efficacy of ivermectin alone and the combination of ivermectin and albendazole on M. perstans microfilaraemia.

Study Design

• Study Type: Interventional
• Allocation: Randomized
• Intervention Model: Single Group Assignment
• Masking: Double
• Primary Purpose: Treatment
• Official Title: Studies on the Epidemiology and Control of Mansonella Perstans Infection in Uganda
• Study Start Date: Nov 1, 2005
• Study Completion Date: Feb 1, 2006

Outcome Measures

Primary Outcome Measures

1. microfilariae periodicity patterns []

2. epidemiology of M. perstans at community level []

3. clinical spectre among infected []

4. reduction in microfilaraemia []

Secondary Outcome Measures

1. treatment effect on clinical manifestations []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 5 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Inclusion Criteria:

• Individuals >= 5 years with or without M. perstans infection

Exclusion Criteria:

• Individuals < 5 years

• Pregnant women

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Luwero	Luwero and Mukono	Luwero and Mukono Districts	Uganda

Sponsors and Collaborators

• DBL -Institute for Health Research and Development
• Ministry of Health, Uganda

Investigators

• Principal Investigator: Asanta M Asio, Msc, Ministry of Health, Uganda

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

• Related Info

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00215280
• Other Study ID Numbers: MV917090205
• First Posted: Sep 22, 2005
• Last Update Posted: Apr 20, 2007
• Last Verified: Apr 1, 2007

• Keywords provided by , ,: Mansonella perstans; microfilaraemia; ivermectin; albendazole; Uganda
• Additional relevant MeSH terms: Dipetalonema Infections; Acanthocheilonemiasis; Mansonelliasis; Lymphedema; Pruritus; Abdominal Pain; Ivermectin; Albendazole

Study Results

No Results Posted as of Apr 20, 2007